These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9331016)

  • 1. Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes.
    Trenkwalder P; Lehtovirta M; Dahl K
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S81-3. PubMed ID: 9331016
    [No Abstract]   [Full Text] [Related]  

  • 2. Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes.
    Trenkwalder P; Dahl K; Lehtovirta M; Mulder H
    Blood Press; 1998 May; 7(3):170-5. PubMed ID: 9758087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA; McVoy HJ; Kaul AF
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients.
    Christensen PK; Lund S; Parving HH
    Kidney Int; 2001 Oct; 60(4):1435-42. PubMed ID: 11576357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of candesartan cilexetil in special patient groups.
    Trenkwalder P
    Blood Press Suppl; 2000; 1():27-30. PubMed ID: 11059633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
    Sever PS
    J Hypertens Suppl; 1997 Dec; 15(6):S9-12. PubMed ID: 9493121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
    Malmqvist K; Kahan T; Dahl M
    Am J Hypertens; 2000 May; 13(5 Pt 1):504-11. PubMed ID: 10826401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candesartan cilexetil. A review of its use in essential hypertension.
    McClellan KJ; Goa KL
    Drugs; 1998 Nov; 56(5):847-69. PubMed ID: 9829158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension.
    Heuer HJ; Schöndorfer G; Högemann AM
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S55-6. PubMed ID: 9331008
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension.
    Andersson OK; Neldam S
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S63-4. PubMed ID: 9331011
    [No Abstract]   [Full Text] [Related]  

  • 11. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension.
    Zanchetti A; Omboni S; Di Biagio C
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S57-9. PubMed ID: 9331009
    [No Abstract]   [Full Text] [Related]  

  • 12. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive effects of candesartan cilexetil, enalapril and placebo.
    Franke H
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S61-2. PubMed ID: 9331010
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
    Bönner G; Fuchs W
    Curr Med Res Opin; 2005 Jun; 21(6):935-40. PubMed ID: 15969893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
    McInnes GT; O'Kane KP; Jonker J; Roth J
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S75-80. PubMed ID: 9331015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Candesartan cilexetil: an update of its use in essential hypertension.
    Easthope SE; Jarvis B
    Drugs; 2002; 62(8):1253-87. PubMed ID: 12010090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S; Stirling AL
    Am J Health Syst Pharm; 2000 Apr; 57(8):739-46. PubMed ID: 10786259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.
    Ogihara T; Arakawa K
    J Hum Hypertens; 1999 Jan; 13 Suppl 1():S27-31; discussion S33-4. PubMed ID: 10076918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
    Zannad F
    Blood Press Suppl; 2000; 1():36-9. PubMed ID: 11059635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure.
    Murayama S; Hirano T; Sakaue T; Okada K; Ikejiri R; Adachi M
    Hypertens Res; 2003 Jun; 26(6):453-8. PubMed ID: 12862201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.